Health News Releases

  • Today May 19
October 30, 2017 10:00
Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Celgene Corporation (NASDAQ:CELG) today announced detailed results from the phase III RADIANCE™ Part B trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phos
October 30, 2017 09:55
Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Celgene Corporation (NASDAQ:CELG) today announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1
October 26, 2017 09:15
Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA® Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients
Janssen’s new once-daily, single tablet combination therapy SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]) has shown to be both highly effective and well-tolerated in
October 20, 2017 09:55
Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Celgene Corporation (NASDAQ:CELG) today announced that new data on the efficacy and safety of ozanimod, a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, in
October 19, 2017 11:09
365mc Unveils World’s First AI-assisted Liposuction System ‘M.A.I.L System’ Developed in Collaboration with Microsoft
365mc, Korea’s first-ever liposuction specialty hospital, has unveiled a Motion capture and Artificial Intelligence-assisted Liposuction System (M.A.I.L System), developed in collaboration with Micros
October 17, 2017 13:35
Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIGTM (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that data from the pivotal Phase 2 ALTA (ALK in Lung Cancer Trial of AP26113) clinical trial evaluating ALUNBRIGTM (brigatinib) in pat
October 17, 2017 11:00
AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification
AstraZeneca and its partner Chi-Med today presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Ph
October 17, 2017 10:10
Results from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017
Celgene Corporation (NASDAQ:CELG) today announced that phase 2 data of investigational compound ozanimod in Crohn’s disease and ulcerative colitis will be presented at the World Congress of Gastroente
October 16, 2017 11:10
FASLODEX (FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB[1]
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for Faslo
October 12, 2017 11:50
Ferring Strengthens Growth Hormone Franchise Zomacton® Through Acquisition of ZomaJet™ Needle-Free Injector Device
Ferring Pharmaceuticals announced today that it has entered into a definitive agreement with Antares Pharma, Inc. to acquire the worldwide rights for the ZomaJet™ needle-free auto injector device.
October 11, 2017 10:40
Herbalife Nutrition Survey Reveals APAC Consumers Concerned About Aging-Related Health Issues but Underestimate the Importance of Nutrition in Healthy Aging
Premier global nutrition company, Herbalife (NYSE: HLF) today released findings from its Asia Pacific Healthy Aging Survey, of 6,000 respondents aged 40 and above from Australia, Hong Kong, India, Ind
October 06, 2017 15:45
Wolters Kluwer Celebrates the 25th Anniversary of UpToDate with Launch of 25th Specialty, Anesthesiology
Wolters Kluwer Health announced today that UpToDate®, the acclaimed evidence-based clinical decision support (CDS) resource, is commemorating its 25th anniversary with the launch of its 25th clinical
October 06, 2017 15:25
Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced final data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed
October 06, 2017 11:30
Bringing Healthcare Home - The Radar Health Monitor That Kyoto University's Center of Innovation and Panasonic Developed Gets a Major Upgrade
In early 2016, researchers from Kyoto University‘s Center of Innovation and Panasonic Corporation developed a radar-based device that could instantaneously and accurately measure the body’s vital sign
SELVAS Healthcare's AI-based Body Composition Analyzer ACCUNIQ BC380
October 02, 2017 17:00
SELVAS Healthcare Launches AI-based Body Composition Analyzer ‘ACCUNIQ BC380’ Worldwide
SELVAS Healthcare has launched a next generation body composition analyzer ACCUNIQ BC380. ACCUNIQ BC380 is a next-generation intelligent body composition analyzer, which reflects the digital healt
October 02, 2017 14:56
Ferring Appoints Klaus Dugi as Executive Vice President and Chief Medical Officer
Ferring Pharmaceuticals announced today that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer, effective immediately. He will be responsible for Global Med
September 29, 2017 13:25
Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trial at 18th World Conference on Lung Cancer
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will present four company-sponsored abstracts, including one oral presentation, at the 18th World Conference on Lung
September 28, 2017 22:05
Replicor Announces Publication of its REP 301 Study in HBV / HDV Co-Infection in The Lancet Gastroenterology & Hepatology
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced tod
September 27, 2017 13:05
European Commission Approves Symtuza® for the Treatment of HIV-1 In Adults and Adolescents in Europe
Janssen-Cilag International NV (Janssen) today announced that the European Commission has approved the use of Symtuza® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF])[1], a once
September 26, 2017 13:25
22nd Century Now Free of Restrictive License Agreement with British American Tobacco
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, is pleased to announce that the 2013 Research License and Commercial Option Agr
September 21, 2017 10:50
6th Annual World Patient Safety, Science & Technology Summit to Be Held in London, England
The Patient Safety Movement Foundation (PSMF) announces that the 6th Annual World Patient Safety, Science & Technology Summit will take place in London on February 23-25, 2018. Rt. Hon. Jeremy Hunt MP
September 20, 2017 18:05
Biosafe Defenses LLC Announces a New Groundbreaking Disinfectant after 10 Years of Research
Biosafe Defenses LLC (formerly Biosafe Technologies LLC), the world leader in the creation of an entirely new class of light-activated disinfectants, antibacterials and biocides for the home, hospital
September 19, 2017 13:10
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’
IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.1 Early diagnosis is vital because without appropriate medical intervention, the opportunity t
September 18, 2017 17:15
Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN®
Bioventus, a global leader in orthobiologics, today announced the first patients have been enrolled in its BONES (Bioventus Observational Non-interventional EXOGEN Studies) clinical development progra
September 18, 2017 16:45
CHMP positive opinion to include RE-CIRCUIT® data for atrial fibrillation patients undergoing catheter ablation in Pradaxa® Summary of Product Characteristics
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for an update to the European Summary of Product Characteristics (SmPC) o
25 per page50 per page75 per page100 per page